Boehringer and OBT in cancer tie-up
May 2, 2013Research and Development, Sales and Marketing Boehringer, Cancer, OBT
Boehringer Ingelheim and UK biotech firm Oxford BioTherapeutics (OBT) have signed a deal to discover novel antibody targets in cancer. …
Court rules against EMA disclosure
May 2, 2013Medical Communications, Research and Development, Sales and Marketing AbbVie, EMA, Roche, transparency
The European Medicines Agency (EMA) has been ordered in an interim ruling by the General Court of the European Union …
Not-for-profit comms agency adds special advisor
May 1, 2013Medical Communications, Sales and Marketing Comprehensive communications
A new not-for-profit marketing and comms consultancy that specialises in healthcare and research has added Professor Martin Gibson to its …
GSK abandons Parkinson’s drug
May 1, 2013Research and Development, Sales and Marketing GSK, IPX066, Parkinson's
GlaxoSmithKline has terminated its three-year old agreement with Impax Pharmaceuticals to develop investigational Parkinson’s disease drug IPX066. “The decision has …
Manufacturing issues block Gilead approvals
May 1, 2013Manufacturing and Production FDA, Gilead
The FDA has blocked approval of two of Gilead Sciences’ HIV drugs because of deficiencies in their marketing applications related …
Life appoints new executive
May 1, 2013Medical Communications, Sales and Marketing Anderson, Life
Creative comms agency Life Healthcare Communications has appointed a new account executive as part of the expansion of its client …
Charity: MS treatment is ‘lottery’
May 1, 2013Sales and Marketing MS, lottery, society
Multiple sclerosis care in the UK is a ‘lottery’ according to research by the MS Society. The charity says that …
Pfizer sales shrink 9 per cent
April 30, 2013Sales and Marketing Ian Read, Lipitor, Pfizer
Pfizer endured another painful cut to its revenues in the first quarter of 2013, with sales down $1.4 billion, or …
Pfizer and Merck create major diabetes alliance
April 30, 2013Research and Development, Sales and Marketing Merck, Pfizer, diabetes
Pfizer and Merck have unveiled a major new alliance in diabetes which is likely to raise the stakes in the …
AstraZeneca backs online NHS passport tool
April 30, 2013Medical Communications, Sales and Marketing NHS, NIHR, app, medication passport
AstraZeneca has provided support to an NHS partner launching an online tool to help patients keep track of their health …
‘Solid’ start for Novartis
April 30, 2013Sales and Marketing Novartis, Q1, sales
Novartis’ sales of pharma products were unchanged in the first quarter of 2013 at $7.9 billion, with pricing flat, the …
Evolution Marketing Research hires senior director
April 30, 2013Medical Communications, Research and Development, Sales and Marketing Evolution marketing research, david hooper
Healthcare marketing agency Evolution Marketing Research has appointed David Hooper to the firm as senior director, Research. Hooper brings more …
Sales rise for AbbVie
April 30, 2013Sales and Marketing AbbVie, Abbott
AbbVie has released its first financial results as a standalone company since separating from Abbott as an $18 billion biopharma …
DH acts on private data
April 29, 2013Medical Communications, Sales and Marketing Hunt, NHS, data
The government has promised that patients will not be forced into having their personal health records shared by doctors and …
GSK submits UMEC monotherapy
April 29, 2013Sales and Marketing COPD, EMA, GSK, UMEC
GlaxoSmithKline has put its investigational once-daily medicine umeclidinium bromide (UMEC) up for scrutiny by European regulators for patients with chronic …
CTCA changes leadership
April 29, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CTCA
The Cancer Treatment Centers of America (CTCA) network has made a change in its executive leadership with the appointment of …
EMA launches ‘black triangle’ post-marketing scheme
April 28, 2013Sales and Marketing EMA, Post-marketing surveillance, black triangle, pharmacovigilance
The European Medicines Agency has unveiled its new ‘black triangle’ post-marketing surveillance system, and the list of drugs that will …
Pfizer’s Xeljanz rejected in Europe
April 28, 2013Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis
Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …
Prostate cancer drug Xtandi gets nod
April 26, 2013Sales and Marketing Xtandi, Zytiga, prostate cancer
Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …
Zyprexa decline hits Lilly
April 26, 2013Sales and Marketing Q1, lilly, zyprexa
Loss of exclusivity on Lilly’s blockbuster antipsychotic Zyprexa in 2011 continued to hit the company hard in the first quarter …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
